Pandemic

NEC and Sumitomo Corporation Sign Strategic Partnership Agreement to Expand Global Sales of the CropScope Agricultural ICT Platform

Retrieved on: 
Monday, March 4, 2024
Sumitomo Corporation, ICT, Economic development, NEC, Soybean, AI, Fertilizer, Food, Learning, Pandemic, Climate change, Agrochemical, Automation, Data analysis, Knowledge, Agriculture, Sumitomo Group, Food security, Population growth, Partnership

TOKYO, Mar 4, 2024 - (ACN Newswire) - NEC Corporation (TSE: 6701) and Sumitomo Corporation (Sumitomo) have signed a strategic partnership agreement to expand global sales of NEC's agricultural ICT platform CropScope.

Key Points: 
  • TOKYO, Mar 4, 2024 - (ACN Newswire) - NEC Corporation (TSE: 6701) and Sumitomo Corporation (Sumitomo) have signed a strategic partnership agreement to expand global sales of NEC's agricultural ICT platform CropScope.
  • Based on this partnership, NEC and Sumitomo aim to develop markets mainly in South America and the ASEAN region by utilizing Sumitomo's global network.
  • Through this partnership, CropScope is initially being introduced on a trial basis to major sugar companies in Thailand and Brazil.
  • Through this partnership, Sumitomo will utilize its global network to expand CropScope's sales area to Thailand, Brazil, and India, aiming for business growth.

Hurco Reports First Quarter Results for Fiscal Year 2024

Retrieved on: 
Friday, March 8, 2024
CNC, Failure, News, Transport, VMX, Pandemic, COVID-19, Steel, Automation, Security (finance), Software, Video game

Orders in the Americas for the first quarter of fiscal year 2024 increased by 6%, compared to the corresponding period in fiscal year 2023, primarily due to increased customer demand for Hurco and Milltronics machines, particularly higher-performance VMX machines.

Key Points: 
  • Orders in the Americas for the first quarter of fiscal year 2024 increased by 6%, compared to the corresponding period in fiscal year 2023, primarily due to increased customer demand for Hurco and Milltronics machines, particularly higher-performance VMX machines.
  • Gross profit for the first quarter of fiscal year 2024 was $9,695,000, or 22% of sales, compared to $12,718,000, or 23% of sales, for the corresponding prior year period.
  • Selling, general, and administrative expenses as a percentage of sales increased in the first quarter of fiscal year 2024 compared to the first quarter of fiscal year 2023 due to the lower volume of sales year-over-year.
  • The effective tax rate for the first quarter of fiscal year 2024 was 27%, compared to 31% in the corresponding prior year period.

Enerflex Ltd. Reports Fourth Quarter 2023 Financial and Operational Results

Retrieved on: 
Wednesday, February 28, 2024
College of Engineering (KNUST), Acquisition, Proxy, Risk, Investment, Energy, News, Natural gas, Management, Growth, Sale, Prospectus, Pandemic, PP, CAD, PP&E, Public expenditure, Depreciation, Risk management

CALGARY, Alberta, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) today reported its financial and operational results for the three months and year ended December 31, 2023. All amounts are presented in Canadian dollars unless otherwise stated.

Key Points: 
  • These adjustments and Enerflex's bank-adjusted net debt to EBITDA ratio are calculated in accordance with, and derived from, the Company's financing agreements.
  • Gross margin before depreciation and amortization is a non-IFRS measure defined as gross margin excluding the impact of depreciation and amortization.
  • The outlook is based on the same assumptions and risk factors set forth above and is based on the Company's historical results of operations.
  • The prospective financial information set forth in this news release should not be relied on as necessarily indicative of future results.

Marquette National Corporation Reports 2023 Annual Results

Retrieved on: 
Monday, February 26, 2024
Tornado, Weather, Flood, Instability, Bank, Sale, MNAT, Pandemic, COVID-19, OTCQX, Bank statement, Summit, Pressure

CHICAGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Marquette National Corporation (OTCQX: MNAT) today reported net income of $16.12 million for the year ended December 31, 2023, compared to net loss of $2.96 million for the year ended December 31, 2022.

Key Points: 
  • CHICAGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Marquette National Corporation (OTCQX: MNAT) today reported net income of $16.12 million for the year ended December 31, 2023, compared to net loss of $2.96 million for the year ended December 31, 2022.
  • The Company recorded earnings per share of $3.69 for 2023 as compared to a loss of $0.68 per share for the year ended December 31, 2022.
  • At December 31, 2023, total assets were $2.142 billion, an increase of $59 million, or 3%, compared to $2.083 billion at December 31, 2022.
  • Marquette National Corporation is a diversified financial holding company and the parent of Marquette Bank, a full-service, community bank that serves the financial needs of communities in Chicagoland.

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Retrieved on: 
Friday, February 23, 2024
Biology, Pandemic, Vaccine, Antibody, Bacteria, Dyadic, Virus, Antigen, Patient, Partnership

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions.

Key Points: 
  • JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions.
  • Mark Emalfarb, Dyadic’s CEO, expressed excitement about advancing the collaboration with the IIBR.
  • Baruch Shahar, the general manager of LSRI, emphasized the collaborative history with Dyadic, which began in January 2018 and expanded during the pandemic.
  • Mr. Shahar highlighted their satisfaction with ongoing work using Dyadic's C1 technology to co-develop vaccines and treatments targeting biological outbreaks, including pandemics and other threats.

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Retrieved on: 
Wednesday, February 21, 2024
Biology, Pandemic, Vaccine, Antibody, Bacteria, Dyadic, Virus, Antigen, Patient, Partnership

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions.

Key Points: 
  • JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions.
  • Mark Emalfarb, Dyadic’s CEO, expressed excitement about advancing the collaboration with the IIBR.
  • Baruch Shahar, the general manager of LSRI, emphasized the collaborative history with Dyadic, which began in January 2018 and expanded during the pandemic.
  • Mr. Shahar highlighted their satisfaction with ongoing work using Dyadic's C1 technology to co-develop vaccines and treatments targeting biological outbreaks, including pandemics and other threats.

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

Retrieved on: 
Wednesday, February 21, 2024
Annual report, Cancer, Holding, STAT3, Pandemic, CUSIP, COVID-19, Patent, Patient, Intellectual property, Eastern Time Zone, Uncertainty, Security (finance), Trust, IND, RNA interference, Cell

Upon the effectiveness of the reverse stock split, every 20 shares of common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock.

Key Points: 
  • Upon the effectiveness of the reverse stock split, every 20 shares of common stock issued and outstanding as of the effective date will be automatically combined into one share of common stock.
  • No fractional shares of common stock will be issued in connection with the reverse stock split.
  • The reverse stock split will not change the par value of the common stock or modify the rights or preferences of the common stock.
  • The Company anticipates that the reverse stock split will reduce the number of shares of the Company’s common stock issued and outstanding from 12,352,664 shares to approximately 617,833 shares.

Adeia Announces Fourth Quarter And Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 20, 2024
Table, Terrorism, Pandemic, GAAP, Risk, Depreciation

SAN JOSE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA) (the “Company” or “Adeia”) today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • To access the call in the U.S., please dial +1 (888) 660-6411, and for international callers, dial +1 (929) 203-0849.
  • All participants should dial in 15 minutes prior to the start of the conference call.
  • The Company also suggests utilizing the webcast link to access the live call and the replay at Q4 2023 Earnings Call Webcast .
  • Forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements.

United States Medical Diagnostics Research Report 2024: Market Impacts of Surging Adoption of Healthcare Wearables and Rising Integration with Artificial Intelligence - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2024
Biotechnology, Health, Technology, Health Technology, Artificial Intelligence, Hospital, Pandemic, PMA, POC, Growth, EHR, Conditional sentence, Urbanization, BioMérieux, Quest Diagnostics, COVID-19, Product type, Abbott Laboratories, Automation, Danaher Corporation, Roche, Artificial intelligence, IVD, Medical device

A few notable trends include surging adoption of healthcare related devices like wearables, emergence of various pandemic diseases, rising integration with Artificial Intelligence and growing awareness for personalized medicine.

Key Points: 
  • A few notable trends include surging adoption of healthcare related devices like wearables, emergence of various pandemic diseases, rising integration with Artificial Intelligence and growing awareness for personalized medicine.
  • The U.S. medical diagnostics market has been segmented on the basis of type, product type and end-users.
  • Depending on the product type, the U.S. medical diagnostics market can be segmented into reagents, instruments and software & services.
  • The report provides a comprehensive analysis of the U.S. medical diagnostics market segmented on the basis of type, product type, end users and region.

Europe Medical Diagnostics Market Insights Report 2024-2028 with Competitive Analysis of Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2024
Medical Devices, Health, Pandemic, Coagulation, POC, Sonic Healthcare, Growth, Immunoassay, Government, Urbanization, Clinical chemistry, Eurofins Scientific, Attention, COVID-19, Quest Diagnostics, Hematology, Medicine, Infection, Diagnosis, Labcorp, IVD, Medical device

The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • European medical diagnostics market is expected to reach US$109.91 billion in 2028, growing at a CAGR of 5.69%, for the time period of 2024-2028.
  • The report provides a comprehensive analysis of the European Medical Diagnostics Market.
  • The company profiles of leading players (Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover) are also presented in detail.